Antibodies for treatment of Clostridium difficile infection

Clinical and Vaccine Immunology

Volumn 21, Issue 7, 2014, Pages 913-923

  Humphreys, David P ^a   Wilcox, Mark H ^b  

^a UCB PHARMA   (Belgium)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMAN; IMMUNOLOGY; PEPTOCLOSTRIDIUM DIFFICILE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; IMMUNOGLOBULIN G;

EID: 84904467481     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00116-14     Document Type: Short Survey

References (98)

1. Bauer MP, Notermans DW, Van Benthem BHB, Brazier JS, Wilcox MH, Rupnik M, Monnet DL, Van Dissel JT, Kuijper EJ. 2011. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 377:63-73. http://dx.doi.org/10.1016/ S0140-6736(10)61266-4.
2. Wullt M, Odenholt I. 2004. A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea. J. Antimicrob. Chemother. 54:211-216. http://dx.doi.org/10.1093/jac/dkh278. (Pubitemid 39028992)
3. Forster AJ, Taljaard M, Oake N, Wilson K, Roth V, Van Walraven C. 2012. The effect of hospital-acquired infection with Clostridium difficile on length of stay in hospital. Can. Med. Assoc. J. 184:37-42. http://dx.doi.org/10.1503/ cmaj.110543.
4. Dubberke ER, Olsen MA. 2012. Burden of Clostridium difficile on the healthcare system. Clin. Infect. Dis. 55:S88 -S92. http://dx.doi.org/10.1093/ cid/cis335.
5. Wiegand PN, Nathwani D, Wilcox MH, Stephens J, Shelbaya A, Haider S. 2012. Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection. J. Hosp. Infect. 81:1-14. http://dx.doi.org/10.1016/j.jhin.2012.02.004.
6. Planche TD, Davies KA, Coen PG, Finney JM, Monahan IM, Morris KA, O'Connor L, Oakley SJ, Pope CF, Wren MW, Shetty NP, Crook DW, Wilcox MH. 2013. Differences in outcome according to C. difficile testing method: a prospective multicentre diagnostic validation study of C. difficile infection. Lancet Infect. Dis. 13:936-945. http://dx.doi.org/10.1016/S1473-3099(13)70200-7.
7. Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A, Minton NP. 2010. The role of toxin A and toxin B in Clostridium difficile infection. Nature 467:711-714. http://dx.doi.org/10.1038/nature09397.
8. Shim JK, Johnson S, Samore MH, Bliss DZ, Gerding DN. 1998. Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet 351:633-636. http://dx.doi.org/10.1016/S0140- 6736(97)08062-8. (Pubitemid 28098446)
9. Villano SA, Seiberling M, Tatarowicz W, Monnot-Chase E, Gerding DN. 2012. Evaluation of an oral suspension of VP20261, spores of nontoxigenic Clostridium difficile strain M3, in healthy subjects. Antimicrob. Agents Chemother. 56:5224-5229. http://dx.doi.org/10.1128/AAC.00913-12.
10. ViroPharma. 22 April 2013. Treatment with VP20621 (non-toxigenic Clostridium difficile; NTCD) in a phase 2 study resulted in high rates of colonization and statistically significant reductions in recurrence of C. difficile infection. ViroPharma press release. ViroPharma Inc., Exton, PA.
11. Bacci S, Molbak K, Kjeidsen MK, Olsen KEP. 2011. Binary toxin and death after Clostridium difficile infection. Emerg. Infect. Dis. 17:976-982. http://dx.doi.org/10.3201/eid/1706.101483.
12. Hensgens MPM, Kuijper EJ. 2013. Clostridium difficile infection caused by binary toxin-positive strains. Emerg. Infect. Dis. 19:1539-1540. http://dx.doi.org/10.3201/eid1909.110814.
13. Walker AS, Eyre DW, Wyllie DH, Dingle KE, Griffiths D, Shine B, Oakley S, O'Connor L, Finney J, Vaughan A, Crook DW, Wilcox MH, Peto TEA. 2013. Relationship between bacterial strain type, host biomarkers, and mortality in Clostridium difficile infection. Clin. Infect. Dis. 56:1589-1600. http://dx.doi.org/10.1093/cid/cit127.
14. Gerding DN, Johnson S, Rupnik M, Aktories K. 2014. Clostridium difficile binary toxin CDT: mechanism, epidemiology, and potential clinical importance. Gut Microbes 5:15-27. http://dx.doi.org/10.4161/gmic.26854.
15. Wang W, Wang EQ, Balthasar JP. 2008. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther. 84:548-558. http://dx.doi.org/10. 1038/clpt.2008.170.
16. Yoshida M, Kobayashi K, Kuo TT, Bry L, Glickman JN, Claypool SM, Kaser A, Nagaishi T, Higgins DE, Mizoguchi E, Wakatsuki Y, Roopenian DC, Mizoguchi A, Lencer WI, Blumberg RS. 2006. Neonatal Fc receptor for IgG regulates mucosal immune responses to luminal bacteria. J. Clin. Invest. 116:2142-2151. http://dx.doi.org/10.1172/JCI27821. (Pubitemid 44162323)
17. Qiao SW, Kobayashi K, Johansen FE, Sollid LM, Andersen JT, Milford E, Roopenian DC, Lencer WI, Blumberg RS. 2008. Dependence of antibody-mediated presentation of antigen on FcRn. Proc. Natl. Acad. Sci. U. S. A. 105:9337-9342. http://dx.doi.org/10.1073/pnas.0801717105.
18. Xu DZ, Huang KL, Zhao K, Xu LF, Shi N, Yuan ZH, Wen YM. 2005. Vaccination with recombinant HBsAg-HBIG complex in healthy adults. Vaccine 23:2658-2664. http://dx.doi.org/10.1016/j.vaccine.2004.10.040. (Pubitemid 40385099)
19. Ye L, Zeng R, Bai Y, Roopenian DC, Zhu X. 2011. Efficient mucosal vaccination mediated by the neonatal Fc receptor. Nat. Biotechnol. 29:158-163. http://dx.doi.org/10.1038/nbt.1742.
20. Sun X, Wang H, Zhang Y, Chen K, Davis B, Feng H. 2011. Mouse relapse model of Clostridium difficile infection. Infect. Immun. 79:2856-2864. http://dx.doi.org/10.1128/IAI.01336-10.
21. Viscidi R, Laughon BE, Yolken R, Bo-Linn P, Moench T, Ryder RW, Bartlett JG. 1983. Serum antibody response to toxins A and B of Clostridium difficile. J. Infect. Dis. 148:93-100. http://dx.doi.org/10.1093/infdis/148.1.93. (Pubitemid 13039317)
22. Bacon AE, III, Fekety R. 1994. Immunoglobulin G directed against toxins A andBof Clostridium difficile in the general population and patients with antibiotic-associated diarrhea. Diagn. Microbiol. Infect. Dis. 18:205-209. http://dx.doi.org/10.1016/0732-8893(94)90021-3. (Pubitemid 24231268)
23. Aronsson B, Granstrom M, Molby R, Nord CE. 1985. Serum antibody response to Clostridium difficile toxins in patients with Clostridium difficile diarrhoea. Infection 3:97-101. (Pubitemid 15030800)
24. Nakamura S, Mikawa M, Nakashio S, Takabatake M, Okado I, Yamakawa K, Serikawa T, Okumura S, Nishida S. 1981. Isolation of Clostridium difficile from the feces and the antibody in sera of young and elderly adults. Microbiol. Immunol. 25:345-351. http://dx.doi.org/10.1111/j.1348-0421.1981.tb00036.x. (Pubitemid 11085793)
25. Kyne L, Warny M, Qamar A, Kelly CP. 2000. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N. Engl. J. Med. 342:390-397. http://dx.doi.org/10.1056/NEJM200002103420604. (Pubitemid 30084537)
26. Lishman A, Al-Jumaili I, Record C. 1981. Antitoxin production in antibiotic-associated colitis? J. Clin. Pathol. 34:414-415. http://dx.doi.org/ 10.1136/jcp.34.4.414. (Pubitemid 11099915)
27. Monaghan T, Robins A, Knox A, Sewell HF, Mahida YR. 2013. Circulating antibody and memory B-cell responses to C. difficile toxins A and B in patients with C. difficile-associated diarrhoea, inflammatory bowel disease and cystic fibrosis. PLoS One 8:e74452. http://dx.doi.org/10.1371/journal.pone.0074452.
28. Kovaiou RD, Herndler-Brandstette D, Grubeck-Loebenstein B. 2007. Age-related changes in immunity: implications for vaccination in the elderly. Expert Rev. Mol. Med. 9:1-17. http://dx.doi.org/10.1017/S1462399407000221. (Pubitemid 46322025)
29. Leav BA, Blair B, Leney M, Knauber M, Reilly C, Lowy I, Gerding DN, Kelly CP, Katchar K, Baxter R, Ambrosino D, Molrine D. 2010. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 28:965-969. http://dx.doi.org/10.1016/j.vaccine.2009. 10.144.
30. Johnson S, Gerding DN, Janoff EN. 1992. Systemic and mucosal antibody responses to toxin A in patients infected with Clostridium difficile. J. Infect. Dis. 166:1287-1294. http://dx.doi.org/10.1093/infdis/166.6.1287.
31. Wullt M, Noren T, Ljungh A, Akerlund T. 2012. IgG antibody response to toxins A and B in patients with Clostridium difficile infection. Clin. Vaccine Immunol. 19:1552-1554. http://dx.doi.org/10.1128/CVI.00210-12.
32. Katchar K, Taylor CP, Tummala S, Chen X, Sheikh J, Kelly CP. 2007. Association between IgG2 and IgG3 subclass responses to toxin A and recurrent Clostridium difficile-associated disease. Clin. Gastroenterol. Hepatol. 5:707-713. http://dx.doi.org/10.1016/j.cgh.2007.02.025. (Pubitemid 46830983)
33. Kyne L, Warny M, Qamar A, Kelly CP. 2001. Association between antibody response to toxin A and protection against recurrent Clostridium difficile. Lancet 357:189-193. http://dx.doi.org/10.1016/S0140-6736(00)03592-3. (Pubitemid 32108091)
34. Lowy IMD, Molrine DC, Leav BA, Blair BM, Baxter R, Gerding DN, Nichol G, Thomas WD, Jr, Leney M, Sloan S, Hay CA, Ambrosino DM. 2010. Treatment with monoclonal antibodies against Clostridium difficile toxins. N. Engl. J. Med. 362:197-205. http://dx.doi.org/10.1056/NEJMoa0907635.
35. Ryan ET, Butterton JR, Smith RN, Carroll PA, Crean TI, Calderwood SB. 1997. Protective immunity against Clostridium difficile toxin A induced by oral immunization with a live, attenuated Vibrio cholerae vector strain. Infect. Immun. 65:2941-2949. (Pubitemid 27264128)
36. Kim PH, Rolfe RD. 1989. Characterisation of protective antibodies in hamsters immunised against Clostridium difficile toxins A and B. Microb. Ecol. Health Dis. 2:47-59. http://dx.doi.org/10.3109/08910608909140200.
37. Giannasca PJ, Zhang ZX, Lei WD, Boden JA, Giel MA, Monath TP, Thomas WD. 1999. Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters. Infect. Immun. 67:527-538. (Pubitemid 29059183)
38. Lyerly DM, Bostwick EF, Binion SB, Wilkins TD. 1991. Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate. Infect. Immun. 59:2215-2218.
39. Kelly CP, Pothoulakis C, Vavva F, Castagliuolo I, Bostwick EF, O'Keane JC, Keates S, Lamont JT. 1996. Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins. Antimicrob. Agents Chemother. 40:373-379. (Pubitemid 26049350)
40. Kink JA, Williams JA. 1998. Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect. Immun. 66:2018-2025. (Pubitemid 28194097)
41. Chow SK, Casadevall A. 2012. Monoclonal antibodies and toxins - a perspective on function and isotype. Toxins 2:430-454. http://dx.doi.org/10. 3390/toxins4060430.
42. Hansen G, Demarest SJ. July 2006. Orally deliverable and anti-toxin antibodies and methods for making them. Patent WO2006071877.
43. Kuehne SA, Collery MM, Kelly ML, Cartman ST, Cockayne A, Minton NP. 2014. Importance of toxin A, toxin B, and CDT in virulence of an epidemic Clostridium difficile strain. J. Infect. Dis. 209:83-86. http://dx.doi.org/10.1093/infdis/ jit426.
44. Geric B, Carman RJ, Rupnik M, Genheimer CW, Sambol SP, Lyerly DM, Gerding DN, Johnson S. 2006. Binary toxin-producing, large clostridial toxin-negative Clostridium difficile strains are enterotoxic but do not cause disease in hamsters. J. Infect. Dis. 193:1143-1150. http://dx.doi.org/10.1086/501368.
45. Papatheodorou P, Hornuss D, Nolke T, Hemmasi S, Castonguay J, Picchianti M, Aktories K. 2013. Clostridium difficile binary toxin CDT induces clustering of the lipolysis-stimulated lipoprotein receptor into lipid rafts. mBio 4(3):e00244-13. http://dx.doi.org/10.1128/mBio.00244-13.
46. Stewart DB, Berg A, Hegarty J. 2013. Predicting recurrence of C. difficile colitis using bacterial virulence factors: binary toxin is the key. J. Gastrointest. Surg. 17:118-125. http://dx.doi.org/10.1007/s11605-012-2056-6.
47. Abougergi MS, Broor A, Cui W, Jaar BG. 2010. Intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis: an observational study and review of the literature. J. Hosp. Med. 5:E1-E9. http://dx.doi.org/10. 1002/jhm.542.
48. Rasmussen SK, Naested H, Müller C, Tolstrup AB, Frandsen TP. 2012. Recombinant antibody mixtures: production strategies and cost considerations. Arch. Biochem. Biophys. 526:139-145. http://dx.doi.org/10.1016/j.abb.2012.07. 001.
49. Lyerly DM, Phelps CJ, Toth J, Wilkins TD. 1986. Characterization of toxins A and B of Clostridium difficile with monoclonal antibodies. Infect. Immun. 54:70-76. (Pubitemid 16021215)
50. Rothman S, Gentry MK. December 1991. Hybridoma cell lines and monoclonal antibodies to Clostridium difficile toxins A and B. US patent US5071759.
51. von Eichel-Streiber C, Harperath U, Bosse D, Hadding U. 1987. Purification of two high molecular weight toxins of Clostridium difficile which are antigenically related. Microb. Pathog. 2:307-318. http://dx.doi.org/10.1016/ 0882-4010(87)90073-8. (Pubitemid 17089536)
52. Davies NL, Compson JE, Mackenzie B, O'Dowd VL, Lightwood DJ, Humphreys DP. 2013. A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model. Clin. Vaccine Immunol. 20:377-390. http://dx.doi.org/10.1128/CVI.00625-12.
53. Staelens D, Van De Wouwer M, Brouwers E, Caluwaerts S, Rottiers P, Vanhoenacker P, Geukens N, Declerck P, Vermeire S, Rutgeerts P, Van Assche G. 2013. In vitro and in vivo characterisation of neutralizing monoclonal antibodies against Clostridium difficile toxins A and B. Gastroenterol. Conf. Dig. Dis. Wk 2013, Orlando, FL 144:S185.
54. Food and Drug Administration. 2013. Guidance for Industry. Codevelopment of two or more new investigational drugs for use in combination. Center for Drug Evaluation and Research, Food and Drug Administration, US Department of Health and Human Services, Silver Spring, MD. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM236669.pdf.
55. Babcock GJ, Broering TJ, Hernandez HJ, Mandell RB, Donahue K, Boatring N, Stack AM, Lowy I, Graziano R, Molrine D, Ambrosino DM, Thomas WD, Jr. 2006. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect. Immun. 74:6339-6347. http://dx.doi.org/10.1128/IAI.00982-06. (Pubitemid 44657416)
56. Taylor CP, Tummala S, Molrine D, Davidson L, Farrell RJ, Lembo A, Hibberd PL, Lowy I, Kelly CP. 2008. Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A. Vaccine 26:3404-3409. http://dx.doi.org/10.1016/j.vaccine.2008.04.042.
57. Yeh CY, Lin CN, Chang CF, Lin CH, Lien HT, Chen JY, Chia JS. 2008. C-terminal repeats of Clostridium difficile toxin A induce production of chemokine and adhesion molecules in endothelial cells and promote migration of leukocytes. Infect. Immun. 76:1170-1178. http://dx.doi.org/10.1128/IAI.01340-07. (Pubitemid 351428078)
58. Marozsan AJ, Ma D, Nagashima KA, Kennedy BJ, Kang Y, Arrigale RR, Donovan GP, Magargal WW, Maddon PJ, Olson WC. 2012. Protection against Clostridium difficile infection with broadly neutralizing antitoxin monoclonal antibodies. J. Infect. Dis. 206:706-713. http://dx.doi.org/10.1093/infdis/jis416.
59. Libby JM, Jortner BS, Wilkins TD. 1982. Effects of the two toxins of Clostridium difficile in antibiotic-associated cecitis in hamsters. Infect. Immun. 36:822-829. (Pubitemid 12101915)
60. Kim PH, Iaconis JP, Rolfe RD. 1987. Immunization of adult hamsters against Clostridium difficile-associated ileocecitis and transfer of protection to infant hamsters. Infect. Immun. 55:2984-2992. (Pubitemid 18008268)
61. Roberts A, McGlashan J, Al-Abdulla I, Ling R, Denton R, Green S, Coxon S, Landon J, Shone C. 2012. Development and evaluation of an ovine anti-body- based platform for treatment of Clostridium difficile infection. Infect. Immun. 80:875-882. http://dx.doi.org/10.1128/IAI.05684-11.
62. Leuzzi R, Spencer J, Buckley A, Brettoni C, Martinelli M, Tulli L, Marchi S, Luzzi E, Irvine J, Candish D, Veggi D, Pansegrau W, Fiashi L, Savino S, Swennen E, Cakici O, Oviedo-Orta E, Giraldi M, Baudner B, D'Urzo N, Maione D, Soriani M, Rappuoli R, Pizza M, Douce GR, Scarselli M. 2013. Protective efficacy induced by recombinant Clostridium difficile toxin fragments. Infect. Immun. 81:2851-2860. http://dx.doi.org/10.1128/IAI.01341-12.
63. Jin K, Wang S, Zhang C, Xiao Y, Lu S, Huang Z. 2013. Protective antibody responses against Clostridium difficile elicited by a DNA vaccine expressing the enzymatic domain of toxin B. Hum. Vaccin. Immunother. 9:63-73. http://dx.doi.org/10.4161/hv.22434.
64. D'Auria KM, Kolling GL, Donato GM, Warren CA, Gray MC, Hewlett EL, Papin JA. 2013. In vivo physiological and transcriptional profiling reveals host responses to Clostridium difficile toxin A and toxin B. Infect. Immun. 81:3814-3824. http://dx.doi.org/10.1128/IAI.00869-13.
65. Cheng LW, Stanker LH, Henderson TD, II, Lou J, Marks JD. 2009. Antibody protection against botulinum neurotoxin intoxication in mice. Infect. Immun. 77:4305-4313. http://dx.doi.org/10.1128/IAI.00405-09.
66. Ma D, Nagashima K, Kennedy B, Donovan GP, Kang Y, Olson WC, Mar S, Tsurushita N, Marozsan AJ. April 2011. Antibodies for the treatment of Clostridium difficile-associated infection and disease. US patent WO11130650A2.
67. Wang H, Sun X, Zhang Y, Li S, Chen K, Shi L, Nie W, Tzipori S, Wang J, Savidge T, Kumar R, Feng H. 2012. A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection. Infect. Immun. 80:2678-2688. http://dx.doi.org/10.1128/IAI.00215-12.
68. Stabler RA, Dawson LF, Phua LTH, Wren BW. 2008. Comparative analysis of BI/NAP1/027 hypervirulent strains reveals novel toxin B-encoding gene (tcdB) sequences. J. Med. Microbiol. 57:771-775. http://dx.doi.org/10.1099/jmm.0.47743- 0. (Pubitemid 351842071)
69. Stabler RA, He M, Dawson L, Martin M, Valiente E, Corton C, Lawley TD, Sebaihia M, Quail MA, Rose G, Gerding DN, Gibert M, Popoff MR, Parkhill J, Dougan J, Wren BW. 2009. Comparative genome and phenotypic analysis of Clostridium difficile 027 strains provides insight into the evolution of a hypervirulent bacterium. Genome Biol. 10:R102. http://dx.doi.org/10.1186/gb- 2009-10-9-r102.
70. Lanis JM, Barua S, Ballard JD. 2010. Variations in TcdB activity and the hypervirulence of emerging strains of Clostridium difficile. PLoS Pathog. 6:e1001061. http://dx.doi.org/10.1371/journal.ppat.1001061.
71. Lanis JM, Heinlem LD, James JA, Ballard JD. 2013. Clostridium difficile 027/BI/NAP1 encodes a hypertoxic and antigenically variable form of TcdB. PLoS Pathog. 9:e1003523. http://dx.doi.org/10.1371/journal.ppat.1003523.
72. Yousaf N, Howard JC, Williams BD. 1986. Studies in cobra venom factor treated rats of antibody coated erythrocyte clearance by the spleen: differential influence of red blood cell antigen number on the inhibitory effects of immune complexes on Fc dependent clearance. Clin. Exp. Immunol. 66:654-660. (Pubitemid 17211748)
73. Davies KA, Hird V, Stewart S, Sivolapenko GB, Jose P, Epenetos AA, Walport MJ. 1990. A study of in vivo immune complex formation and clearance in man. J. Immunol. 144:4613-4620. (Pubitemid 20224092)
74. Jacob SS, Sebastian JC, Hiorns D, Jacob S, Mukerjee PK. 2004. Clostridium difficile and acute respiratory distress syndrome. Heart Lung 33:265-268. http://dx.doi.org/10.1016/j.hrtlng.2004.04.003. (Pubitemid 38887339)
75. Qualman SJ, Petric M, Karmali MA, Smith CR, Hamilton SR. 1990. Clostridium difficile invasion and toxin circulation in fatal pediatric pseudomembranous colitis. Am. J. Clin. Pathol. 94:410-416. (Pubitemid 20316564)
76. Steele J, Chen K, Sun X, Zhang Y, Wang H, Tzipori S, Feng H. 2012. Systemic dissemination of Clostridium difficile toxins A and B is associated with severe, fatal disease in animal models. J. Infect. Dis. 205:384-391. http://dx.doi.org/10.1093/infdis/jir748.
77. Murase T, Eugenio L, Schorr M, Hussack G, Tanha J, Kitkova EN, Klassen JS, Ng KKS. 2014. Structural basis for antibody recognition in the receptor-binding domains of toxins A and B from Clostridium difficile. J. Biol. Chem. 289:2331-2343. http://dx.doi.org/10.1074/jbc.M113.505917.
78. Frey SM, Wilkins TD. 1992. Localization of two epitopes recognized by monoclonal antibody PCG-4 on Clostridium difficile toxin A. Infect. Immun. 60:2488-2492.
79. Sauerborn M, Hegenbarth S, Laufenberg-Feldmann R, Leukel P, Von Eichel-Streiber C. 1994. Monoclonal antibodies discriminating between Clostridium difficile toxins A and B, p 510-511. In Freer J, et al. (ed), Bacterial protein toxins. Gustav Fischer Verlag, Stuttgart, Germany.
80. Demarest SJ, Hariharan M, Elia M, Salbato J, Jin P, Bird C, Short JM, Kimmel BE, Dudley M, Woodnutt G, Hansen G. 2010. Neutralisation of Clostridium difficile toxin A using antibody combinations. MAbs 2:190-198. http://dx.doi.org/10.4161/mabs.2.2.11220.
81. Lyerly DM, Johnson JL, Frey SM, Wilkins TD. 1990. Vaccination against lethal Clostridium difficile enterocolitis with nontoxic recombinant peptide of toxin A. Curr. Microbiol. 21:29-32. http://dx.doi.org/10.1007/BF02090096. (Pubitemid 20308134)
82. Torres JF, Lyerly DM, Hill JE, Monath TP. 1995. Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters. Infect. Immun. 63:4619-4627.
83. Ward SJ, Douce G, Dougan G, Wren BW. 1999. Local and systemic neutralizing antibody responses induced by intranasal immunization with the nontoxic binding domain of toxin A from Clostridium difficile. Infect. Immun. 67:5124-5132. (Pubitemid 29455282)
84. van Dissel JT, De Groot N, Hensgens CMH, Numan S, Kuijper EJ, Veldkamp P, Van't Wout J. 2005. Bovine antibody enriched whey to aid in the prevention of a relapse of Clostridium difficile-associated diarrhoea: preclinical and preliminary clinical data. J. Med. Microbiol. 54:197-205. http://dx.doi.org/10. 1099/jmm.0.45773-0. (Pubitemid 40868008)
85. Ghose C, Kalsy A, Sheikh A, Rollenhagen J, John M, Young J, Rollins SM, Qadri F, Calderwood SB, Kelly CP, Ryan ET. 2007. Transcutaneous immunization with Clostridium difficile toxoid A induces systemic and mucosal immune responses and toxin A-neutralizing antibodies in mice. Infect. Immun. 75:2826-2832. http://dx.doi.org/10.1128/IAI.00127-07. (Pubitemid 46870163)
86. Gardiner DF, Rosenberg T, Zaharatos J, Franco D, Ho DD. 2009. A DNA vaccine targeting the receptor binding domain of Clostridium difficile toxin A. Vaccine 27:3598-3604. http://dx.doi.org/10.1016/j.vaccine.2009.03.058.
87. Tian JH, Fuhrmann SR, Kluepfel-Stahl S, Carman RJ, Ellingsworth L, Flyer DC. 2012. A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models. Vaccine 30:4249-4258. http://dx.doi.org/10.1016/j.vaccine.2012.04.045.
88. Steele J, Mukherjee J, Parry N, Tzipori S. 2013. Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease. J. Infect. Dis. 207:323-330. http://dx.doi.org/10.1093/ infdis/jis669.
89. Lyerly DM, Saum KE, Macdonald DK, Wilkins TD. 1985. Effects of Clostridium difficile toxins given intragastrically to animals. Infect. Immun. 47:349-352. (Pubitemid 15169828)
90. Modi N, Gulati NG, Solomon K, Monaghan T, Robins A, Sewell HF, Mahida YR. 2011. Differential binding and internalization of Clostridium difficile toxin A by human peripheral blood monocytes, neutrophils and lymphocytes. Scand. J. Immunol. 74:264-271. http://dx.doi.org/10.1111/j.1365-3083.2011.02578.x.
91. Von Eichel-Streiber C, Moos M. December 2006. Amino acid sequences for therapeutic and prophylactic use against diseases due to Clostridium difficile toxins. US patent US7151159.
92. Kamiya S, Yamakawa K, Meng XQ, Ogura H, Nakamura S. 1991. Production of monoclonal antibody to Clostridium difficile toxin A which neutralises enterotoxicity but not haemagglutinin activity. FEMS Microbiol. Lett. 81:311-316. http://dx.doi.org/10.1111/j.1574-6968.1991.tb04778.x.
93. Koon HW, Shih DQ, Hing TC, Yoo JH, Ho S, Chen X, Kelly CP, Targan SR, Pothoulakis C. 2013. Human monoclonal antibodies against Clostridium difficile toxins A and B inhibit inflammatory and histologic responses to the toxins in human colon and peripheral blood monocytes. Antimicrob. Agents Chemother. 57:3214-3223. http://dx.doi.org/10.1128/AAC.02633-12.
94. He X, Sun X, Wang J, Wang X, Zhang Q, Tzipori S, Feng H. 2009. Antibody-enhanced, Fc gamma receptor-mediated endocytosis of Clostridium difficile toxin A. Infect. Immun. 77:2294-2303. http://dx.doi.org/10.1128/IAI. 01577-08.
95. He X, Wang J, Steele J, Sun X, Nie W, Tzipori S, Feng H. 2009. An ultrasensitive rapid immunocytoxicity assay for detecting Clostridium difficile toxins. J. Microbiol. Methods 78:97-100. http://dx.doi.org/10.1016/j.mimet.2009. 04.007.
96. Hussack G, Arbabi-Ghahroudi M, Van Faassen H, Songer JG, Ng KKS, Mackenzie R, Tanha J. 2011. Neutralisation of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domain. J. Biol. Chem. 286:8961-8976. http://dx.doi.org/10.1074/jbc.M110.198754.
97. Zhang C, Jin K, Xiao Y, Cheng Y, Huang Z, Wang S, Lu S. 2013. Potent monoclonal antibodies against Clostridium difficile toxin A elicited by DNA immunization. Hum. Vaccin. Immunother. 9:2157-2164.
98. Takada K, Watanabe M, Torashima T, Nakajima K. 2013. Human monoclonal antibodies against toxins A and B of Clostridium difficile. Poster B11. Antibody Eng. Therapeut. Conf.